NEW YORK, June 4 (Reuters) - Bankrupt genetic testing

company 23andMe told a U.S. bankruptcy judge on

Wednesday that it wants to re-open bidding on its assets,

including customers' genetic data, after receiving a $305

million offer from its co-founder Anne Wojcicki.

23andMe had previously selected a $256 million bid from

Regeneron Pharmaceuticals ( REGN ) as the lead offer after a

bankruptcy auction concluded in May.

But it received a later bid from TTAM Research Institute, a

new nonprofit founded by Wojcicki, and asked U.S. Bankruptcy

Judge Brian Walsh in St. Louis, Missouri, to be allowed to

re-engage with potential buyers after determining that TTAM had

sufficient financing to proceed with the higher offer.

Regeneron is willing to make a new bid for 23andMe's assets,

but wants a $10 million breakup fee if Wojcicki's bid is

ultimately accepted, its attorney Emil Kleinhaus told the judge.

Kleinhaus said Regeneron still wants to buy 23andMe, but

believes that it was unfair for the genetic testing company to

seek a "do-over" after its earlier auction.

"The auction was over, the rules were clear," Kleinhaus

said.

South San Francisco, California-based 23andMe filed for

bankruptcy in March, seeking to sell its business at auction

following a decline in consumer demand and a 2023 data breach

that exposed sensitive genetic and personal information of

millions of customers.

The bankruptcy sale will include more than 15 million

customer DNA profiles, collected via 23andMe's popular

direct-to-consumer saliva-testing kits.

The data breach and subsequent bankruptcy filing have drawn

scrutiny from U.S. lawmakers concerned that the company's

genetic data on millions of customers could be sold to

unscrupulous buyers.

23andMe had named TTAM as the backup bidder after its

earlier auction, valuing its offer at $146 million.